Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- A Lilly-ImClone Deal May Offer the Drama that CEO Lechleiter Craves
- Today came the news that Eli Lilly is one of the mystery suitors in the ImClone deal that Bristol-Myers Squibb was just booted from. If CEO John Lechleiter were to scoop up ImClone -- thus bolting on the cancer specialist's pipeline to replace the absence of its...
- Blog posts 2008-09-29
Additional Resources
- Eli Lilly settles Zyprexa suit for $1.42-billion
- NEW YORK — Drug maker Eli Lilly is pleading guilty to a charge that it illegally marketed anti-psychotic drug Zyprexa for off-label use, and will pay a combined $1.42-billion (U.S.) to settle civil suits and end the criminal investigation. The Indianapolis-based company will pay $800-million to settle civil suits, including...
- News items 2009-08-07
- Lilly Apologizes for Wrongful Zyprexa Promotion; Still Shovelling Cash Into Settlement Furnace
- Another quarter, another $80 million in "not meaningful" charges for Eli Lilly. The company reported its Q4 2008 results yesterday, and as usual the income statement contained a lump devoted to money lost on "asset impairments, restructuring and other special charges." With the new charge for $80...
- Blog posts 2009-01-30
- In Zyprexa Settlement, Lilly Fritters Away 7.2 Percent of Revenues
- Eli Lilly is close to settling criminal and civil charges related to its mismarketing of Zyprexa for $1.4 billion, the New York Times reports. The settlement will mean that Lilly will have disgorged $3.1 billion in charges, mostly for Zyprexa, since 2006. That's about 7.2 percent of its revenues over...
- Blog posts 2009-01-21
- Eli Lilly Needs New Drugs To Counter Prozac Ruling.(Brief Article)
- Zyprexa, Zovant, Forteo and Evista could be blockbusters. ELI LILLY & Co., faced with maintaining its revenues after its blockbuster Prozac fluoxetine goes off patent in 2001, is running out of options. The company's longterm pipeline is Zyprexa, Zovant,...
- Research articles 2000-09-25
- Pharma Roundup: Merck CEO Admits Failure, Lilly's New Zyprexa Delay, and More
- Merck CEO admits Merck's mistakes, Lilly's long-acting Zyprexa formulation delayed again by FDA, VC funding goes on, Actavis for sale by John Maas
- Blog posts 2009-01-08
- Costly new treatments for schizophrenia not more effective: US study
- WASHINGTON AFP — New drugs for schizophrenia are no more effective than older, less expensive ones, according to a US government study. The study published in The New England Journal of Medicine, which confirms what many psychiatrists have suspected for some time, compared the new generation of four "atypical"...
- Research articles 2005-09-20
- Eli Lilly Jumps to Defense of Zyprexa Manic-Depression Drug.(Knight Ridder/Tribune Business News)
- Dec. 13--Trying to defend its leading treatment for manic depression, Abbott Laboratories said its drug outperformed an up-and-coming Eli Lilly and Co. drug in a new study. Dec. 13--Trying to defend its leading treatment for manic depression, Abbott Laboratories said its drug outperformed an...
- Research articles 2000-12-13
- AstraZeneca's "Smoke and Mirrors" Man Has New Job in Medical Writing
- Whatever happened to AstraZeneca's "smoke and mirrors" man, Richard Lawrence? You remember him. He was the one who, in 1997, wrote a memo about Seroquel that praised the company's efforts to put a "positive spin" on "this cursed study," and added: I am not 100% comfortable with this data...
- Blog posts 2009-04-06
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- Lilly Profit Tops Estimates on Drug Sales, Taxes
- By Lewis Krauskopf NEW YORK (Reuters) - Eli Lilly and Co LLY posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, sending shares up 1.9 percent. Sales of lung cancer treatment Alimta, anti-depressant Cymbalta, Humalog insulin and schizophrenia...
- News items 2009-10-21
- Newer Antipsychotic Drugs Double Heart Risk, Just Like Older Meds
- The prevailing wisdom that the latest generation of antipsychotics is safer than older medicines takes a hit in the current issue of the New England Journal of Medicine. A study comparing the drugs finds: Patients taking the newer group of drugs, called atypicals, are twice as likely to suffer sudden...
- News items 2009-08-07
- Eli Lilly Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question comes Roopesh Patel with UBS please go ahead. Roopesh Patel - UBS Thank you. I have a couple of questions, first on Cymbalta. In light of the recent slowdown in market share trends over the past five months, I was just wondering,...
- Earnings calls 2007-10-18
- FDA Approves Extended Use of Eli Lilly's Antipsychotic Drug.(Knight Ridder/Tribune Business News)
- Nov. 14--Zyprexa has become the first new-style antipsychotic to be approved for long-term treatment of schizophrenia. Nov. 14--Zyprexa has become the first new-style antipsychotic to be approved for long-term treatment of schizophrenia.
- Research articles 2000-11-14
- Lilly's Schizophrenia Drugs Both Disappoint
- Derek Lowe submits: Over the years of this blog, I’ve occasionally made comments about how no one really knows much about how drugs for the major central nervous system diseases work. Well, actually, I’ve stated things more forcefully than that, but you get the idea. And although many people...
- External links 2009-03-30
- Eli Lilly & Co. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from the line Tim Anderson with Sanford Bernstein. Please go ahead. Jay Olsen - Sanford Bernstein Good morning, this is Jay Olsen for Tim Anderson. I have two questions. First, can you update us on what impact you might...
- Earnings calls 2009-01-29
- Harvard's Biederman: "Save Me From NYT's Gardiner Harris!"
- Dr. Joseph Biederman, the controversial Harvard child psychiatrist who promoted the use of Johnson & Johnson's Risperdal antipsychotic in children, is begging a New Jersey judge to save him from New York Times reporter Gardiner Harris. Harris also sucks as a reporter, Biederman alleges in a letter...
- Blog posts 2009-03-20
- Pfizer to Pay Record $2.3 Billion to Settle Charges
- By Jeremy Pelofsky and Ransdell Pierson WASHINGTON/NEW YORK (Reuters) - Pfizer Inc agreed on Wednesday to plead guilty to a criminal charge relating to promotions of its now-withdrawn Bextra pain medicine and will pay a record $2.3 billion to settle allegations it improperly marketed 13 medicines. The world's biggest drugmaker...
- News items 2009-09-02
- Eli Lilly & Co. Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionThank you. [Operator Instructions]. Our first question is from the line of David Risinger from Merrill Lynch. Please go ahead. David Risinger - Merrill Lynch Yes, thanks very much. Thank you for all the detail on the financial results. Just looking forward to next week, could you please...
- Earnings calls 2008-01-29
- Five Masters of the Boardroom
- Challenging times call for extraordinary board members who can thwart corporate chaos. Here are five who shine. img.boardmember {border:4px solid #edece7; background:#fff; padding:4px; float:right; margin:0px 0 10px 10px; } ...
- Articles 2008-10-15
- << Previous
- page 1 of 1
- Next >>
